Ratio Therapeutics On BMS Buy-In, Radiopharma R&D Trends, AI And Assets

Scrip’s senior editor Vibha Ravi speaks with Jack Hoppin, CEO and chairman, and John Babich, chief scientific officer, at Ratio Therapeutics, about the company’s radiopharmaceuticals pipeline, investment by BMS, use of AI, trends and developments in radiopharma research like combining ADCs or PARP inhibitors and more. https://scrip.citeline.com/SC150098/Ratio-Therapeutics-On-BMS-Investment-Radiopharma-RD-Trends-AI-Use

Episode metadata supplied by the publisher feed · Published Apr 16, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Ratio Therapeutics On BMS Buy-In, Radiopharma R&D Trends, AI And Assets

0:00 39:09

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Citeline Podcasts?

This episode is 39 minutes long.

When was this Citeline Podcasts episode published?

This episode was published on April 16, 2024.

Can I download this Citeline Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!